Core Viewpoint - Xianjian Technology (01302) has shown a significant increase in stock price and continues to lead in the cardiovascular and peripheral vascular interventional medical device market, with a strong focus on innovation and global expansion [1][2]. Group 1: Company Performance - As of July 30, Xianjian Technology's stock price rose by 5.42%, reaching 2.14 CNY per share, with a trading volume of 46.69 million CNY [1]. - For the fiscal year ending 2024, the company reported total revenue of 1.304 billion CNY and a net profit of 222 million CNY [2]. Group 2: Product and Market Position - The company specializes in the research, development, and production of medical devices for cardiovascular and peripheral vascular interventions, holding a leading position in the domestic market [1]. - Xianjian Technology has expanded its products to over 120 countries and regions globally, demonstrating its international growth strategy [1]. - The company has secured 2,426 high-quality patents and has 15 products that have passed the NMPA innovative medical device review process, indicating a strong commitment to technological advancement [1].
先健科技(01302)上涨5.42%，报2.14元/股